CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
G-Pump™ (glucagon infusion)drug
Likely dose
G-Pump™ (glucagon infusion) 0.3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02733588
NCT02733588Phase 2Completed
CompareCT.gov

A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients

Xeris Pharmaceuticals·interventional·Posted Apr 11, 2016·Updated Oct 30, 2018

In Brief

A Phase 2 clinical trial evaluating G-Pump™ (glucagon infusion) for Hypoglycemia and Complications of Bariatric Procedures. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe hypoglycemia following bariatric surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia, Complications of Bariatric Procedures
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 11, 2016
Enrollment StartMar 1, 2016
Primary CompletionApr 5, 2017
Study CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.2 years ago

Interventions

G-Pump™ (glucagon infusion)drug

0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump